Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
State Street Corporation reported beneficial ownership of common stock of Perspective Therapeutics, Inc.. State Street reported beneficially owning 6,051,771 shares of common stock, representing 5.3% of the class. All reported voting and dispositive authority is shared, with 5,942,306 shares subject to shared voting power and 6,051,771 shares subject to shared dispositive power, and no shares subject to sole voting or dispositive power.
The filing identifies subsidiaries involved in the holdings, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, each classified as an investment adviser. The filing states that no other person is known to have rights to dividends or sale proceeds relating to more than 5% of the class.
Perspective Therapeutics, Inc. provides an updated corporate presentation describing a strategy to “redefine oncology treatment” with next‑generation radiopharmaceuticals built around the alpha‑emitting isotope 212Pb. The company emphasizes engineering the “alpha advantage,” careful isotope selection, and a theranostic approach to treating solid tumors.
The presentation outlines a direct‑to‑hospital delivery model supported by integrated isotope production and daily regional manufacturing of ready‑to‑administer products. Lead programs include VMT‑α‑NET for SSTR2+ neuroendocrine tumors, VMT01 targeting MC1R for melanoma, and PSV359 targeting FAP‑ɑ in advanced solid tumors, all in ongoing Phase 1/2a studies.
Slides reference deepening responses over time and durable disease control for VMT‑α‑NET, preliminary anti‑tumor activity and tolerability for VMT01, improved tumor retention for PSV359, and a broad intellectual‑property portfolio across the radiopharmaceutical value chain, supported by experienced leadership in radiopharmaceutical and drug development.
BlackRock, Inc. reported beneficial ownership of 7,776,940 shares of Perspective Therapeutics Inc. common stock, representing 6.8% of the class as of June 30, 2026. BlackRock has sole voting power over 7,679,840 shares and sole dispositive power over all 7,776,940 shares, with no shared voting or dispositive power. The filing aggregates holdings of certain BlackRock business units, while other disaggregated business units are excluded. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Perspective Therapeutics’ outstanding common shares.
Perspective Therapeutics, Inc. has a significant shareholder group reporting ownership of its common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 6,036,999 shares of common stock, representing 5.3% of the class.
The reporting persons disclose no sole voting or dispositive power over these shares, but shared voting and shared dispositive power over all 6,036,999 shares. The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related investment managers, and the group states that this structure should not, by itself, be construed as an admission of beneficial ownership.
Perspective Therapeutics, Inc. filed an 8-K to note that it updated its corporate presentation on July 1, 2026. The new presentation highlights its focus on next-generation radiopharmaceuticals for oncology, centered on 212Pb-based therapies and an integrated production and delivery model.
The materials describe a diverse pipeline targeting solid tumors, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma, and PSV359 for FAP-α–expressing solid tumors, all in ongoing phase 1/2a trials. The deck also emphasizes a theranostic approach, regional manufacturing, and direct-to-hospital delivery to support ready-to-administer products.
Perspective Therapeutics, Inc. Schedule 13G shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared voting and dispositive power over 4,893,883 shares of Common Stock, representing 4.3% of the class. The filing states they acquired beneficial ownership above 5% on 06/23/2026 but ceased to be beneficial owners above 5% by the filing date.
The cover pages list shared voting power and shared dispositive power of 4,893,883 shares. A Joint Filing Agreement dated June 29, 2026 is attached and the signatures show the filing was signed on 06/29/2026.
Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation on June 1, 2026 and furnished it as Exhibit 99.1. The presentation highlights a strategy focused on next-generation radiopharmaceuticals using the 212Pb isotope to treat solid tumors through a theranostic approach and integrated isotope production.
The deck describes regional daily production and direct-to-hospital delivery, along with a wholly owned 212Pb-based oncology portfolio. Key programs include VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-ɑ in solid tumors, all in ongoing Phase 1/2a or early clinical trials, with references to safety, exposure, and preliminary anti-tumor activity.
Perspective Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 114,017,755 common shares entitled to vote, 97,882,462 shares were represented, an 85.85% quorum. Stockholders elected six directors to serve until the 2027 annual meeting.
They also ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026. In an advisory vote on the frequency of say-on-pay, a one-year interval received the most support, and the company intends to hold annual advisory votes on executive compensation.
Perspective Therapeutics reported interim clinical results that will be highlighted at the 2026 ASCO meeting for all three of its 212Pb radiopharmaceutical programs. Updated data for [212Pb]VMT-α-NET in neuroendocrine tumors show a safety profile without dose-limiting toxicities or serious renal complications across 64 treated patients, and investigator-assessed responses in multiple cohorts with continued deepening of tumor shrinkage over time.
In metastatic melanoma, the [212Pb]VMT01 3.0 mCi monotherapy cohort showed two confirmed responders among seven heavily pre-treated patients, with six experiencing stable disease or partial response and no dose-limiting toxicities or Grade 4–5 events. For [212Pb]PSV359 in FAP-positive solid tumors, treatment has advanced to Cohort 3 at 6.0 mCi, with earlier cohorts showing only Grade 1–2 adverse events and no dose-limiting toxicities. Overall, the company emphasizes that all three programs remain well-tolerated and plans further data updates in late 2026.
Perspective Therapeutics, Inc. amendment to a Schedule 13G shows Morgan Stanley reporting shared voting power of 2,930,734 shares and shared dispositive power of 2,959,296 shares in the issuer's common stock. The filing states the position equals 2.6% of the class.
The filing includes the statement, verbatim, that "As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities." The form lists CUSIP 46489V302 and is signed by an authorized Morgan Stanley signatory on 05/12/2026.